ToplineShares of Tylenol-maker Kenvue jumped more than 6% as trading opened Tuesday, a day after President Donald Trump linked the use of the drug’s active ingredient during pregnancy to increased risk for autism, despite lacking scientific evidence. Economists saw "limited" risk to the pharmaceutical firm's stock, despite some expected impact on Tylenol consumption.Getty ImagesKey FactsKenvue shares rose about 6.2% to around $18 as trading opened Tuesday, following an earlier rally in premarket while rebou ...